Annovis

Study Title: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease (Annovis)

Purpose

The Annovis Study at UCLA is currently seeking adults aged 55–85 to participate in a clinical trial evaluating an oral medication for early Alzheimer’s Disease. This medication targets amyloid, a protein that can build up in the brain and disrupt communication between brain cells. Amyloid buildup is believed to play a key role in the development and progression of Alzheimer’s Disease.

Approximately 760 participants from around 100 centers in the United States will participate in this study. UCLA aims to recruit 10 participants for the study.
Participants will:

• Take a daily oral medication or placebo for 18 months
• Attend regular clinic visits for health checkups, cognitive assessments, and questionnaires (including visits at screening, enrollment, months 1, 3, 6, 9, 12, 15, and 18)
• Receive volumetric MRI scans at months 6 and 18
• Complete brief phone calls before and after clinic visits

(PI: Pauline Wu, DO, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)

Contact: Kagan Clinical Trials Program at (310) 794-6191 or send an email to EastonClinicalTrials@mednet.ucla.edu to participate in this study or for more information.

More information on the Annovis study is available at clinicaltrials.gov ID#: NCT06709014.